Post by babaoriley on Apr 4, 2014 13:44:53 GMT -5
Been ugly for biotech in general, and certainly, more generally, NASDAQ.
Our price moves until FDA approval are merely noise, the only reason I do not ignore them totally is because an opportunity may present itself. After approval, then the baloney starts on all the stuff we already know, no partner being paramount among them. Once there is a partner, MNKD shifts strongly toward the "investment" part of the spectrum, and far away from gambling, of course, subject to the normal risks that attend any stock and any biotech stock, like the one harshal mentioned on another thread.
A couple of sales to foreign countries wouldn't hurt.
Our price moves until FDA approval are merely noise, the only reason I do not ignore them totally is because an opportunity may present itself. After approval, then the baloney starts on all the stuff we already know, no partner being paramount among them. Once there is a partner, MNKD shifts strongly toward the "investment" part of the spectrum, and far away from gambling, of course, subject to the normal risks that attend any stock and any biotech stock, like the one harshal mentioned on another thread.
A couple of sales to foreign countries wouldn't hurt.